Matches in SemOpenAlex for { <https://semopenalex.org/work/W180420909> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W180420909 endingPage "21" @default.
- W180420909 startingPage "917" @default.
- W180420909 abstract "It is reported on the induction of abortion in the second trimenon and the induction of labour at term with the prostaglandins PGF2alpha and PGE2 under consideration of pharmacokinetic problems as well as special indications such as secondary insufficiency of labour and certain fields of applications like softening and priming. The prostaglandin in gelform and the prostaglandin analogue 15(S)-15-methyl-PGF2alpha are discussed as well as the possible advantages and side-effects of these substances.A review is made of the clinical use of prostaglandins in obstetrics and gynecology. Second trimester abortions can be induced by the transcervical extraamniotic, transabdominal intraamniotic, or intravenous injection of PGF2 alpha or PGE2. The use of these agents is currently the method of choice for this procedure. Studies have been made of methods of application which will lead to improved effectiveness and of the use of prostaglandins in combination with oxytocin. The use of prostaglandin analogues, which are metabolized more slowly than the natural prostaglandins, provides the advantages of decreased side effects and a decreased need of additional doses. The side effects associated with prostaglandin use include nausea, vomiting, diarrhea, heat waves, shivering, headache, dizziness, elevated temperatures, and leucocytosis. The mortality rate reported in a 4-year survey is 10.5/100,000 which compared favorably with the 17.7/100,000 for saline abortions. Prostaglandin gels can be used to soften and dilate the cervix in preparation for an abortion or induction of labor with no undesired side effects and without the use of laminarias. Labor can be induced by the administration of the prostaglandins F2 alpha and E2 either intravenously or, in the case of the latter, orally. Treatment with PGE2 can also continue parturition in cases of secondary insufficiency of labor. Research is currently being conducted in the use of these substances for fertility control." @default.
- W180420909 created "2016-06-24" @default.
- W180420909 creator A5023480282 @default.
- W180420909 date "1978-01-01" @default.
- W180420909 modified "2023-09-23" @default.
- W180420909 title "Application of prostaglandins in obstetrics and gynecology." @default.
- W180420909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/742314" @default.
- W180420909 hasPublicationYear "1978" @default.
- W180420909 type Work @default.
- W180420909 sameAs 180420909 @default.
- W180420909 citedByCount "1" @default.
- W180420909 countsByYear W1804209092023 @default.
- W180420909 crossrefType "journal-article" @default.
- W180420909 hasAuthorship W180420909A5023480282 @default.
- W180420909 hasConcept C121608353 @default.
- W180420909 hasConcept C126322002 @default.
- W180420909 hasConcept C131872663 @default.
- W180420909 hasConcept C2776176026 @default.
- W180420909 hasConcept C2777740455 @default.
- W180420909 hasConcept C2778642596 @default.
- W180420909 hasConcept C2779234561 @default.
- W180420909 hasConcept C2780580376 @default.
- W180420909 hasConcept C2780664492 @default.
- W180420909 hasConcept C2780852908 @default.
- W180420909 hasConcept C2781258859 @default.
- W180420909 hasConcept C2909370928 @default.
- W180420909 hasConcept C42219234 @default.
- W180420909 hasConcept C54355233 @default.
- W180420909 hasConcept C71924100 @default.
- W180420909 hasConcept C86803240 @default.
- W180420909 hasConceptScore W180420909C121608353 @default.
- W180420909 hasConceptScore W180420909C126322002 @default.
- W180420909 hasConceptScore W180420909C131872663 @default.
- W180420909 hasConceptScore W180420909C2776176026 @default.
- W180420909 hasConceptScore W180420909C2777740455 @default.
- W180420909 hasConceptScore W180420909C2778642596 @default.
- W180420909 hasConceptScore W180420909C2779234561 @default.
- W180420909 hasConceptScore W180420909C2780580376 @default.
- W180420909 hasConceptScore W180420909C2780664492 @default.
- W180420909 hasConceptScore W180420909C2780852908 @default.
- W180420909 hasConceptScore W180420909C2781258859 @default.
- W180420909 hasConceptScore W180420909C2909370928 @default.
- W180420909 hasConceptScore W180420909C42219234 @default.
- W180420909 hasConceptScore W180420909C54355233 @default.
- W180420909 hasConceptScore W180420909C71924100 @default.
- W180420909 hasConceptScore W180420909C86803240 @default.
- W180420909 hasIssue "5-6" @default.
- W180420909 hasLocation W1804209091 @default.
- W180420909 hasOpenAccess W180420909 @default.
- W180420909 hasPrimaryLocation W1804209091 @default.
- W180420909 hasRelatedWork W1507685352 @default.
- W180420909 hasRelatedWork W1594963030 @default.
- W180420909 hasRelatedWork W2021577921 @default.
- W180420909 hasRelatedWork W2049680671 @default.
- W180420909 hasRelatedWork W2053960391 @default.
- W180420909 hasRelatedWork W2088404515 @default.
- W180420909 hasRelatedWork W2169759311 @default.
- W180420909 hasRelatedWork W2397681522 @default.
- W180420909 hasRelatedWork W2184726854 @default.
- W180420909 hasRelatedWork W2465532742 @default.
- W180420909 hasVolume "37" @default.
- W180420909 isParatext "false" @default.
- W180420909 isRetracted "false" @default.
- W180420909 magId "180420909" @default.
- W180420909 workType "article" @default.